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Summary
Background In September, 2012, the UN Commission on Life Saving Commodities (UNCoLSC) outlined a plan to 
expand availability and access to 13 life saving commodities. We proﬁ le global and country progress against these 
recommendations between 2012 and 2015.
Methods For 12 countries in sub-Saharan Africa that were oﬀ -track to achieve the Millennium Development Goals for 
maternal and child survival, we reviewed key documents and reference data, and conducted interviews with ministry 
staﬀ  and partners to assess the status of the UNCoLSC recommendations. The RMNCH fund provided short-term 
catalytic ﬁ nancing to support country plans to advance the commodity agenda, with activities coded by UNCoLSC 
recommendation. Our network of technical resource teams identiﬁ ed, addressed, and monitored progress against 
cross-cutting commodity-related challenges that needed coordinated global action.
Findings In 2014 and 2015, child and maternal health commodities had fewer bottlenecks than reproductive and 
neonatal commodities. Common bottlenecks included regulatory challenges (ten of 12 countries); poor quality 
assurance (11 of 12 countries); insuﬃ  cient staﬀ  training (more than half of facilities on average); and weak supply 
chains systems (11 of 12 countries), with stock-outs of priority commodities in about 40% of facilities on average. The 
RMNCH fund committed US$175·7 million to 19 countries to support strategies addressing crucial gaps. 
$68·2 million (39·0%) of the funds supported systems-strengthening interventions with the remainder split across 
reproductive, maternal, newborn, and child health. Health worker training ($88·6 million, 50·4%), supply chain 
($53·3 million, 30·0%), and demand generation ($21·1 million, 12·0%) were the major topics of focus. All priority 
commodities are now listed in the WHO Essential Medicines List; appropriate price reductions were secured; quality 
manufacturing was improved; a fast-track registration mechanism for prequaliﬁ ed products was established; and 
methods were developed for advocacy, quantiﬁ cation, demand generation, supply chain, and provider training. Slower 
progress was evident around regulatory harmonisation and quality assurance.
Interpretation Much work is needed to achieve full implementation of the UNCoLSC recommendations. Coordinated 
eﬀ orts to secure price reductions beyond the 13 commodities and improve regulatory eﬃ  ciency, quality, and supply 
chains are still needed alongside broader dissemination of work products. 
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Introduction 
The Every Woman Every Child (EWEC) movement was 
established in 2010 by the UN Secretary General to 
address the major health challenges facing women and 
children around the world.1 Under this umbrella, the 
ﬁ rst Global Strategy for Women’s and Children’s 
Health was launched as a roadmap to enhance 
ﬁ nancing, strengthen policy, and improve service 
delivery for the most vulnerable women and children. 
It drew attention to the estimated 8 million children 
dying of preventable causes each year and the 
350 000 women dying of complications related to 
pregnancy and childbirth.2 
Persistent gaps in availability of and access to life 
saving commodities (medicines and medical devices) 
were identiﬁ ed as major obstacles to achieving universal 
basic health care for pregnant women and children.3 
Estimates suggested that, across low-income countries, 
just a third to half of children received basic drugs to 
treat childhood diarrhoea and pneumonia (appendix). 
Similarly, only a third of women received appropriate 
management for the major causes of maternal death: 
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eclampsia and post-partum haemor rhage. For newer 
commodities such as implantable contraceptives, zinc 
for diarrhoea, and intravenous antibiotics for sepsis in 
newborns, coverage levels were near zero (appendix).
A series of global consultations in 2011 explored 
strategies to overcome crucial gaps. Barriers included 
the paucity of aﬀ ordable products and age-appropriate 
formulations; weak supply chains; inadequate 
regulatory capacity; and little awareness of where, 
when, and how to use essential medicines and medical 
devices.4 Establish ment of a high-level commission 
was recommended as a mechanism to synthesise 
technical evidence and identify innovative actions to 
rapidly increase availability, access, and rational use of 
key commodities. 
The UN Commission on Life Saving Commodities 
(UNCoLSC) launched its Report3 and Implementation 
Plan5 in September, 2012, highlighting 13 underused, low-
cost, and high-impact commodities across reproductive, 
maternal, newborn, and child health (RMNCH) that if 
implemented at scale could make the greatest impact in 
reducing preventable deaths. The report included ten 
recommendations for addressing key systemic 
bottlenecks, including strategies to shape global and local 
markets; improve regulatory eﬃ  ciency; enhance medicine 
quality and safety; strengthen supply chains; improve 
health worker performance; augment demand; and 
stimulate product innovation (ﬁ gure 1). The commodities 
provided a concrete and actionable focus for eﬀ orts across 
this continuum, acting as tracers to help identify and 
address barriers to eﬀ ective intervention delivery. 
To advance this agenda, a steering committee was 
established to draw together stakeholders throughout 
RMNCH with the aim of enhancing coordination 
between UN agencies, partner organisations, pro-
grammes, and countries. To accelerate implementation, 
direct technical and ﬁ nancial support was provided to a 
subset of EWEC countries selected on the basis of being 
oﬀ -track to achieve the Millennium Development Goals 
for maternal and child survival. Building on International 
Health Partnership principles,6 an RMNCH country 
engagement process was initiated that included a joint, 
rapid multistakeholder synthesis of the existing plans 
and subplans relevant to a particular country context; a 
prioritisation process, based on the RMNCH situation 
analysis, the burden of disease, and speciﬁ c pro-
grammatic and ﬁ nancial gaps across the RMNCH 
continuum of care; and the commitment of development 
Research in context
Evidence before this study 
Original coverage estimates for the 13 life saving commodities 
and related reproductive, maternal, newborn, and child health 
(RMNCH) interventions identiﬁ ed in the UNCoLSC report were 
generated using the Lives Saved Tool for 49 countries of the 
world with the lowest income plus India (appendix). Evidence 
on potential systemic bottlenecks inﬂ uencing coverage such as 
regulatory hurdles, supply chain weakness, or training gaps are 
partial and fragmented. This evidence exists in 
non-standardised formats at the country level and includes 
policy documents, essential medicines lists, treatment 
guidelines, health facility assessments, and routine 
performance monitoring platforms such as health and logistics 
management information systems. 
Added value of this study
This multicountry assessment used the conceptual framework 
implicit in the UNCoLSC recommendations to systematically 
track the 13 priority RMNCH commodities across the 
continuum—from manufacturing through to utilisation and 
coverage for the post-2012 period. We generated a 
standardised set of indicators for each recommendation, 
drawing from the range of best-available data sources outlined 
above. Country-level bottlenecks that were identiﬁ ed through 
this process informed the prioritisation and ﬁ nancing of 
national RMNCH plans. Challenges identiﬁ ed across multiple 
countries informed evolving global eﬀ orts. 
Implications of all the available evidence
Much needs to be done to achieve full implementation of the 
UNCoLSC recommendations. Coordinated global action will be 
required to enhance market shaping, secure price reductions, 
improve regulatory eﬃ  ciency, enhance the quality and safety of 
medicines, and strengthen supply chains. Translation of the 
latest evidence, tools, and best-practice materials developed 
through the UNCoLSC and related global initiatives to the 
country level will require robust and sustained technical 
assistance. Further harmonisation and alignment of RMNCH 
monitoring tools and systems is essential.
13 life-saving commodities
Accelerate
achievement
of Millennium
Development
Goals 4 and 5
Reproductive
health
Female condoms
Implants
Emergency contraception
Maternal
health
Oxytocin
Misoprostol
Magnesium sulfate
Newborn
health
Injectable antibiotics
Antenatal corticosteroids
Chlorhexidine
Resuscitation equipment
Child
health
Amoxicillin
Oral rehydration salts
Zinc
Ten recommendations
1 Shaping global market
2 Shaping delivery markets
3 Innovative ﬁnancing
4 Quality strengthening
5 Regulatory eﬃciency
6 Supply and awareness
7 Demand and awareness
8 Reaching women and children
9 Performance and accountability
10 Product innovation
Figure 1: UNCoLSC recommendations to improve access to 13 life saving commodities
UNCoLSC=UN Commission on Life Saving Commodities.
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Commodity or 
systems related
Bottleneck deﬁ nition
RMNCH coordination*
Coordination mechanism Systems A national coordination mechanism that fulﬁ ls three  or fewer of the following criteria: membership with a diverse representation, 
under the leadership of a government agency, has a terms of reference specifying activities to be carried out, meets at least twice 
per year, or has meeting minutes available
RMNCH plan costed and budgeted Systems A national RMNCH plan that does not fulﬁ l one of the criteria: costed interventions, subnational level detail, or identiﬁ es funding 
sources or budget allocation for the costed interventions
Commodity security strategy Systems A national RMNCH commodity security strategy that does not cover commodities across all RMNCH service delivery areas or has 
not been approved by the Ministry of Health
Innovative ﬁ nancing
Results-based ﬁ nancing mechanism Systems A result-based ﬁ nancing programme that includes life saving commodities is piloted only in select areas or is non-existent
Regulatory eﬃ  ciency
National  EML Commodity Commodity is not included on the EML within context-appropriate formulation
National treatment guidelines Commodity National treatment guideline that is unclear or has signiﬁ cant deviations from up-to-date WHO guidelines 
Registered in-country Commodity Commodity without at least one brand fully registered in-country under any formulation
Prescription authority Commodity For oral rehydration solution, zinc, amoxicillin, emergency contraceptives, and female condoms: commodity is not authorised for 
distribution by community health workers or private sector vendors without a prescription
For all other commodities, commodity is not authorised for distribution at the primary health-care facility 
Quality strengthening
Good manufacturing 
practices-accredited manufacturers 
Systems Valid good manufacturing practices accreditation is not required for both domestic and international public sector procurement 
of RMNCH commodities
National medicines control laboratory Systems No national medicines control laboratory is certiﬁ ed by any standard accreditation agency
Medicine quality monitoring Systems A medicine quality monitoring system that does not fulﬁ l all of these criteria: medicines are sampled from all levels of the health 
system, sampling and testing take place regularly, and regulatory action has been taken as a result of ﬁ ndings in the last 
12 months
Patient safety monitoring 
(pharmacovigilance)
Systems A patient safety monitoring (pharmacovigilance) system that does not fulﬁ l one of these criteria: active with at least 20 suspected 
adverse drug reactions reported in the last 12 months, regulatory action has been taken as a result of ﬁ ndings in the last 
12 months  
Supply and awareness
Forecasting tools Systems Forecasting tools for RMNCH commodities and devices that are not used annually or do not use at least two of three data 
methods (consumption-based, morbidity, health services) 
Comprehensive national eLMIS Systems A national eLMIS that does not fulﬁ l one of the criteria: automatically compiles and aggregates information; provides updated 
information at least once per month; tracks RMNCH commodity availability and distribution from ﬁ rst point of warehousing to 
the health facility
Supply chain training to districts Systems Training in supply chain management has not been deployed to all public sector district-level health facilities
Tracked in eLMIS Commodity Commodity-speciﬁ c availability is not tracked from ﬁ rst point of warehousing to health facility by an electronic logistics 
management information system 
National level stock-outs Commodity A stock-out of the commodity occurred at national level in the past 12 months
Stock-out in health facilities Commodity More than 20% of health facilities (eg, point-of-service locations) had a stock-out of the commodity at time of assessment
Performance and accountability
Training curricula (national) Commodity For the respective service area, national level in-service training curriculum is unclear or has substantial deviations from up-to-date 
WHO guidelines 
Recent training at health facilities Commodity For the respective service area, more than 40% of health facilities did not have a health worker who has been recently trained 
(within the past 1–2 years based on data source)
Job aids or check lists (national) Commodity For the respective service area, national level job aids or checklists are unclear or have signiﬁ cant deviations from up-to-date WHO 
guidelines
Job aids or checklists at health facilities Commodity For the respective service area, more than 40% of health facilities did not have relevant job aids or checklists at time of assessment
Reaching women and children
Policy against user fees Commodity For the respective service area, national policy regarding user fees does not meet all of the following criteria: covers all costs 
related to life saving commodities (eg, not a sliding scale), covers both life saving commodities and related services, and covers all 
relevant populations and levels of care  
Demand and utilisation
Demand generation Systems The national RMNCH plan does not include costed demand generation or behaviour change initiatives for RMNCH
Coverage rate Commodity For family planning commodities: less than 15% of aﬀ ected population receive treatment with appropriate life saving commodity
For all other commodities: less than 60% of aﬀ ected population receive treatment with appropriate life saving commodity
RMNC= reproductive, maternal, newborn, and child health. UNCoLSC=UN Commission on Life Saving Commodities. EML=Essential Medicines List. eLMIS=electronic logistics management information system. 
*RMNCH Coordination is a performance indicator but not a UNCoLSC recommendation.
Table 1: Deﬁ nitions of UNCoLSC system-related and commodity-speciﬁ c bottleneck indicators
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partners to support implementation of prioritised 
interventions, under Ministry leadership. Although the 
potential range of support was broad and country-driven, 
the commodity focus of UNCoLSC remained central to 
help identify, prioritise, and track progress against key 
bottlenecks. A Strategy and Coordination Team 
comprised of representatives of WHO, the United 
Nations Population Fund, and UNICEF worked as a 
secretariat to help with implementation of these eﬀ orts.
In summary, three main strategies were introduced to 
further the UNCoLSC recommendations: an RMNCH 
situation analysis across a range of countries to 
systematically identify commodity-related and systems-
related bottlenecks, a country engagement process to 
provide technical and ﬁ nancial support to national 
RMNCH plans, and a network of technical resource 
teams to address global bottlenecks and support country 
implementation. 
This Article reviews progress against these strategies in 
the 3 years since the UNCoLSC report. With the 2015 
launch of the updated Global Strategy for Women’s, 
Children’s and Adolescents’ Health7 and new Global 
Financing Facility,8 which aim to reduce preventable 
deaths and improve the quality of life for women, 
children, and adolescents until 2030, we describe how 
lessons learned through implementing the UNCoLSC 
recommendations should inform this ambitious agenda.
Methods
RMNCH situation analysis 
We did an RMNCH situation analysis in 12 of the 
19 countries that received grants from the RMNCH trust 
fund in sub-Saharan Africa. The remaining six countries 
were recent fund recipients, with the timing of the 
situation analysis at the discretion of national ministries. 
Between January, 2013, and September, 2015, we collected 
data from the Democratic Republic of Congo, Cameroon, 
Ethiopia, Kenya, Malawi, Mali, Nigeria, Senegal, Sierra 
Leone, Tanzania, Uganda, and Zambia. 
The situation analysis relied on maximising the use of 
existing data sources across RMNCH, which included a 
review of the latest information from national strategic 
plans, essential medicine and medical device lists, 
training materials, and other related documents. Where 
available, we compiled aggregated indicators from 
nationally representative health facility assessments or 
health and logistics management information systems, 
alongside the most recent population-based survey data. 
We conducted semi-structured interviews with 
programme managers, procurement and regulatory 
agencies, and local experts to verify and complement the 
data sources. Assessments were done in each country 
over a 1–2 week period by a trained RMNCH facilitator 
supported by the RMNCH Strategy and Coordination 
Team in collaboration with ministries, UN country 
teams, and relevant partners. After each assessment, the 
RMNCH Strategy and Coordination Team helped with 
quality assurance procedures, analysis, and content 
reviews in collaborating organisations.
Before conducting the situation analysis, we undertook 
a standardisation process to generate a core set of 
indicators with clear performance thresholds. We used 
the UNCoLSC framework to inform the choice of 
indicators, highlighting systemic and commodity-related 
bottlenecks at each level of the health-care system (table 1). 
Standard performance ranges (from 1, weakest, to 5, 
strongest) were deﬁ ned for each indicator in consultation 
with the global network of UNCoLSC technical resource 
teams to show diﬀ erences in systemic and programmatic 
conditions (appendix). During each country assessment, 
we compared results of structured question sets with the 
standard performance cutoﬀ s to generate categorical 
performance scores (from 1, weakest, to 5, strongest). 
These scores produced a standard rating that could be 
compared over time and across countries. A bottleneck is 
deﬁ ned as moderate-to-weak performance for a particular 
indicator (see table 1 for indicator-speciﬁ c deﬁ nitions). 
We entered results into a relational database (MS 
Access, Microsoft, 2013), processed the results (R version 
3.2.0, 2015), and uploaded the data to a web-based 
RMNCH commodity TRTs
• Synthesis of research and evidence
• Identiﬁed commodity-speciﬁc barriers and solutions
• Guide product speciﬁcation
• Facilitate new product innovation
• Advise on treatment guidelines
• Technical input for job aids, checklists, and training materials
• Targeted support to country-level activities
Global regulation, markets, 
and policy
• Global market shaping
• Identiﬁcation and negotiation 
   of price reductions
• Manufacturer mapping
• Support for quality manufacturing
• Updating WHO and national 
• Essential Medicines Lists and 
   treatment guidelines
• Product pre-qualiﬁcation
• Fast-track registration of priority
   commodities
• Deﬁne procurement standards
• Facilitate joint inspections
• Support for regional and
   in-country quality assurance
   and post-market surveillance
• Support to pharmacovigilance
   eﬀorts
Advocacy TRT
• Coordination with wider 
   EWEC advocacy
• Design advocacy toolkit and
   messaging framework
• Technical assistance for 
   country-led policy change
Digital health TRT
• Create inventory of e-health 
   and m-health tools and best 
   practice
• Coordination of technical
   support for country 
   programmes
Supply chain
• Generation and synthesis of
   best-practice materials
• Harmonisation of 
   key performance indicators
• ICT support for LMIS systems
• ICT innovations for decentralised
   monitoring
• Quantiﬁcation guidance
• Support for commodity security
   strategies
• Technical support to countries
   and partners
Demand, access, and 
performance
• Synthesis of demand generation
   evidence
• Develop demand generation
   toolkits
• Technical support to 
   programmes and stakeholders
• Mapping of user-fees and access
   barriers
• Revolving fund for commodity
   procurement
• Policy options for fee exemption
   strategies
• Design and deploy high quality,
   adaptable job aids, checklists, 
   and training materials
Figure 2: UNCoLSC technical resource teams and areas of work
UNCoLSC=UN Commission on Life Saving Commodities. TRT=technical resource team. EWEC=Every Woman Every 
Child. ICT=information and communication technologies. LMIS=logistics management information system. 
RMNCH=reproductive, maternal, newborn, and child health. e-health=electronic health. m-health=mobile health.
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platform. A dashboard was created to provide visual 
representation of bottlenecks across RMNCH for a single 
or several countries. Detailed descriptions of methods 
and performance ratings are provided in the appendix. 
RMNCH country engagement process 
We monitored country progress in several ways. A 
representative of the RMNCH Strategy and Coordination 
Team supported the country engagement process, and 
formally documented the process using a range of 
purpose-based tools and systems that articulated the 
prioritised RMNCH plan, costs, and resource con-
tributions from domestic and partner sources. The 
UNCoLSC commodity and recommendation area coded 
budgeted activities from the RMNCH fund grants. Country 
teams reported 6-monthly progress by use of standard 
templates, with periodic country visits in many cases. 
Progress against global milestones
Global eﬀ orts to advance the UNCoLSC mandate were 
the responsibility of a network of technical resource 
teams, who addressed cross-cutting challenges that 
required coordinated global action, which included 
priorities and targets outlined in the UNCoLSC 2012 
report and a wider range of related activities. 
About 450 experts from 85 organisations established 
nine thematic teams: four focusing on commodity areas 
(one each for the RMNC components), three focusing on 
systemic areas (global regulation, markets, and policy; 
supply chain; and demand access and performance); and 
two cross-cutting themes of digital health and advocacy. 
An interagency review panel reviewed work plans for 
each team. Figure 2 proﬁ les each team and related work 
stream.
Progress against key milestones was documented 
through a range of methods including: monthly 
coordination calls, biannual global meetings, an annual 
workplan reporting against speciﬁ c objectives, and a 
synthesis of relevant global documents and work products. 
Role of the funding source
The funders had no role in the design, conduct, analysis, 
and writing up of the study. The corresponding author 
had full access to all data.
≤20%
21–40%
41–60%
61–80%
81–100%
No data
Countries with bottlenecks (%)
Regulatory eﬃciency Supply and awareness Performance and
accountability 
Supply and awareness Performance and
accountability 
Female condom 3/12 7/12 5/12
Implant 6/12 4/12 5/12
Emergency contraceptive 7/12 6/12 5/12
Oxytocin 2/12 5/12 3/12
Misoprostol 7/12 6/10 3/12
Magnesium sulfate 6/12 7/12 3/12
Injectable antibiotic 6/12 6/12 7/12
Antenatal steroid 10/12 6/11 7/12
Chlorhexidine 9/12 5/9 7/12
Neonatal resuscitation 2/12 7/9 7/12
Amoxicillin 9/12 7/10 0/12
Oral rehydration solution 3/12 6/11 0/12
Zinc 7/12 7/11 0/12
RMNCH coordination Innovative ﬁnancing Supply and awareness Quality 
strengthening
10/12 8/12 11/12 11/12
Systems-related indicators:                                                                                         National-level bottlenecks
Commodity-related indicators:                                                                                   National-level bottlenecks                                                                               
Commodity
by RMNC service area
Population
Demand and 
utilisation
• Policy against user 
fees
• Coverage rates
6/12 7/10 9/10 10/10
6/12 6/10 9/10 12/12
6/12 6/9 9/10 3/3
6/12 4/11 10/10 No data
6/12 9/9 10/10 No data
6/12 7/11 10/10 No data
6/12 5/10 7/7 No data
6/12 6/9 7/7 No data
6/12 3/3 7/7 No data
6/12 1/2 7/7 No data
6/12 6/9 4/5 10/10
6/12 2/6 4/5 8/12
6/12 4/5 4/5 9/9
Demand and 
utilisation
• Demand generation
4/12
Facility-level bottlenecks
• National Essential 
Medicines List
• National treatment 
guidelines
• Registered in-country
• Prescription authority
• Tracked in eLMIS
• National level 
stock-outs
• Training curriculum
• Job aids or checklists
Reaching women and 
children
• Stock-out in health 
facilities 
• Recent training at 
facilities
• Job aids or checklists 
at facilities 
• Coordination 
mechanism
• RMNCH plan costed 
and budgeted
• Commodity security 
strategy
• Procure GMP-
accredited 
manufacturers
• National medicines 
control lab
• Medicine quality  
• Patient safety
• Forecasting tools
• Comprehensive 
national eLMIS
• Supply chain training 
to districts
• Results-based 
ﬁnancing 
mechanism 
Figure 3: Number of countries with bottlenecks by UNCoLSC recommendation, level of health-care system, and RMNC service area
Denominators change due to absence of data in some countries for some indicators. UNCoLSC=UN Commission on Life Saving Commodities. RMNCH=reproductive, maternal, newborn, and child 
health. EML=Essential Medicines List. eLMIS=electronic logistics management information system. GMP=good manufacturing practice. 
For more information on the 
teams and work streams see 
http://www.lifesaving
commodities.org
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Results 
The proportions of countries with a bottleneck by 
UNCoLSC recommendation, commodity, and sector of 
the health-care system are summarised in ﬁ gure 3. For 
each recom mendation, a bottleneck is deﬁ ned as 
moderate-to-weak performance on any indicator within a 
recom mendation. For example, regulatory eﬃ  ciency was 
a bottleneck if the commodity was not on the national 
Essential Medicines List (EML) in the preferred formu-
lation, treatment guidelines were absent or in complete, or 
the preferred formulation was not registered in-country or 
had restricted prescription authority (table 2, appendix). 
Systems-related bottlenecks were identiﬁ ed in all 
countries. Ten of 12 countries had a weakness in RMNCH 
Cameroon Democratic 
Republic of 
Congo
Ethiopia Kenya Mali Malawi Nigeria Senegal Sierra Leone Tanzania Uganda Zambia Average
Reproductive
Female condom 66% 58% 93% 80% 74% 25% 10% 12% 12% .. 89% .. 52%
Implant 46% 78% 22% 25% 63% 11% 6% 4% 20% .. 71% .. 35%
Emergency contraceptives 71% 87% 31% 15% .. 20% 15% 86% 27% .. 36% .. 43%
Maternal
Oxytocin 9% 10% 3% 49% .. 5% 16% 22% 18% 6% 50% 23% 19%
Misoprostol 71% .. 21% 90% .. 89% 84% 99% 65% 55% 85% 73%
Magnesium sulfate 49% 78% 11% 74% .. 15% 49% 65% 14% 11% 67% 68% 46%
Newborn
Injectable antibiotics .. 8% 3% 47% .. 9% 18% 47% 15% 28% 31% 73% 28%
Antenatal steroids 7% 11% 8% 84% .. 84% 42% 96% 42% .. 76% .. 50%
Chlorhexidine .. .. .. .. 64% .. 51% .. .. 25% .. 47%
Neonatal resuscitation .. .. .. .. 11% .. .. .. .. 91% .. 51%
Child
Amoxicillin .. 16% .. 31% .. 24% .. 48% 47% 21% 72% 8% 33%
Oral rehydration solution .. .. .. 26% .. 9% .. .. 10% 13% 21% 5% 14%
Zinc .. .. .. 37% .. 24% .. .. 19% 46% 31% 31%
Average (mean) 46% 43% 24% 51% 69% 30% 30% 53% 26% 26% 57% 35% 40%
Percentages derived from secondary data sources (appendix).
Table 2: Proportion of health facilities with stock-out at the time of assessment for 13 life saving commodities. 
US$0·9 m (0·5%)
US$0 m (0·0%)
 
US$3·7 m  
US$53·3 m (30·3%)
 
US$4·5 m (2·6%)
 
US$21·1 m (12·0%)
 
US$2·6 m (1·5%)
 
US$0·3 m (0·2%)
 
US$1·3 m (0·8%) 
US$88·6 m 
(50·4%)
 
Selected examples BudgetUNCoLSC
recommendation
Countries
(total=19)
1 Shaping global
 delivery markets
2 Shaping local 
 delivery markets
3 Innovative
 ﬁnancing
4 Quality
 strengthening
5 Regulatory 
 eﬃciency
6 Supply and 
 awareness
7 Demand and 
 utilisation
8 Reaching women 
 and children
9 Performance and 
 accountability
10 Product innovation
0
3
6
8
10
19
19
6
19
3
Not funded through country plans
Mapping of market size and manufacturing capacity
Supporting local manufacturers with new product introduction
PBF strategies implemented or planned
Prequaliﬁcation of new products by regulatory agencies, building 
post-market surveillance capacity, training drug inspectors
Update of Essential Medicines Lists, treatment guidelines with 
Life Saving Commodities
District level quantiﬁcation, m-health tools for stock monitoring, 
integrated LMIS systems, commodity purchase
Community mobilisation, advocacy eﬀorts, printing and dissemination 
of media materials
Maternal health vouchers, telecommunication toll-free numbers 
for calls to ambulance
Staﬃng, training, mentorship, and support supervision 
Development of job aids, checklists across countries
Innovative ways to package products, zinc and oral rehydration solution, 
misoprostol, magnesium sulfate
Figure 4: Distribution of committed funds by UNCoLSC recommendation (US$175·7 million, 19 countries)
UNCoLSC=UN Commission on Life Saving Commodities. PBF=performance-based ﬁ nancing. eLMIS= logistics management information system. m-health=mobile health.
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Panel 1: Examples of country achievements to improve access to life-saving commodities (2013–14) 
Democratic Republic of Congo
• Established a third-party payment coupon system for 
RMNCH commodities through family kits 
• Updated National Standard Treatment Guidelines and the 
Essential Medicines List
• Printed copies of standards and guidelines on RMNCH for all 
health facilities 
• Updated Essential Medicines List to include all 13 priority 
commodities
Ethiopia
• Supported manufacturers to make high-quality 
chlorhexidine for the domestic market 
• Produced media materials to increase demand for female 
condoms and emergency contraception
• Trained health extension workers on implantable 
contraception insertion and removal
• Procured essential commodities, including amoxicillin, 
gentamicin, ceftriaxone, and oral rehydration solution
Malawi
• Revised the National Standard Treatment Guidelines and 
Essential Medicines List to include all 13 priority 
commodities
• Revised, printed, and distributed Logistics Management 
Information System forms
• Trained health workers on stock and logistics management 
and use of essential commodities
• Initiated quarterly review of quantiﬁ cations and introduced 
supply-chain management as an agenda in the zonal 
quarterly review meetings
• Procured dexamethasone, chlorhexidine, and neonatal 
resuscitation equipment
• Introduced post-market quality surveillance for RMNCH drugs
• Introduced supportive supervision for supply chain 
management
• Initiated a mobile phone stock-tracking system for 
peripheral facilities (cStock)
• Engaged community leaders to improve RMNCH service 
uptake
• Introduced national emergency obstetric and newborn care 
assessment 
• Trained health workers in four districts on the insertion and 
removal of contraceptive implants
Nigeria
• Provided technical support for local manufacturing of 
chlorhexidine and zinc or oral rehydration solution, with the 
entry of four new oral rehydration solutions and ﬁ ve zinc 
suppliers to the local market, resulting in reductions in 
wholesale price of nearly 80% 
• Introduced performance-based ﬁ nancing to track and 
improve commodity use
• Registered chlorhexidine, zinc or oral rehydration solution, 
and misoprostol (pending)
• Instigated fast-track registration process for UNCoLSC 
commodities
• Initiated discussions on supply-chain integration, trained 
health workers on eLMIS in seven states
• Arranged community distribution of misoprostol and 
chlorhexidine in ﬁ ve states
• Introduced conditional cash transfer programmes in eight 
priority states and community health insurance schemes 
• Trained health-care workers from eight states to administer 
misoprostol, magnesium sulfate, and oxytocin; job aids 
printed and distributed to health facilities
• Trained trainers for implantable contraceptives, ongoing 
cascade training in six states 
• Developed messaging materials on pneumonia case 
management
Senegal
• Updated Essential Medicines List and hired pharmacist 
inspector
• Trained community stakeholders in RMNCH service package 
to strengthen community-level provision 
• Procured transport and information technology equipment 
to strengthen supply chains
• Began studies on morbidity and mortality in children aged 
under 5 years, and on cord care
Sierra Leone
• Systematic roll-out of all approved procurement lists, 
guidelines, and updated protocols 
• Integrated RMNCH training for health workers 
• Competency-based training in long-acting family planning 
methods
• All health facilities trained in Helping Babies Breathe 
newborn resuscitation 
• Ensured health facilities are Basic Emergency Obstetric and 
Newborn Care-compliant
• Conducted demand generation for RMNCH through 
maternal child health weeks 
• Scaled up integrated community case management for 
community health workers
• Scaled up performance-based ﬁ nance scheme
Uganda
• Achieved 60% reduction in import price for zinc and oral 
rehydration solutions
• Developed, pretested, and automated the RMNCH 
scorecards
• Proﬁ led and assessed the existing manufacturers of 
chlorhexidine and dispersible amoxicillin
• Ministry of Health signed an addendum to the Uganda 
Clinical Guidelines and Essential Medicines and Health 
Supplies List to include all 13 life saving commodities
(Panel contines on next page)
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Panel 2: Global achievements by UNCoLSC technical resource teams and related partners
Shaping global markets
• Global price reductions of 50% have been secured for 
implantable contraceptives with major increases in 
procurement and availability
• Achievable cost per use of the Non-pneumatic Anti-Shock 
Garment reduced by over 75%, from US$1·30 to below 
$0·30, following agreement with manufacturer
• Agreements have been signed with three quality 
manufacturers of neonatal bag and mask resuscitator which 
could achieve a 30–40% price reduction
• Needs-based forecast algorithms have been developed for 
all commodities and demand-based forecasts are 
underway to better estimate global manufacturing 
requirements
Shaping local delivery markets
• Major manufacturers for all 13 commodities have been 
identiﬁ ed, including for newly listed commodities such as 
chlorhexidine and amoxicillin dispersible tablets
• Three manufacturers in Nigeria, two manufacturers in 
Kenya, and one manufacturer in Bangladesh were assessed 
for GMP compliance and received additional technical 
assistance to ensure quality of 7·1% chlorhexidine 
digluconate for umbilical cord care
• Regional market-shaping eﬀ orts were conducted with the 
East African Community pharmaceutical industry to 
strengthen its competitive position and market share
Innovative ﬁ nancing
• A multicountry study is underway to assess the feasibility of 
providing governments with a revolving fund to secure 
better price, quality, and delivery of RMNCH commodities
• Results-based ﬁ nancing strategies have been developed and 
successfully implemented to incentivise the reduction of 
stock-outs
Quality strengthening
• A post-market quality survey of the 13 commodities has 
been conducted in 10 countries 
• The WHO collaborating centre in Ghana developed a model 
pharmacovigilance programme
• Four local manufacturers have now achieved quality 
certiﬁ cation in Nigeria, with additional support provided to 
manufacturers in ﬁ ve other EWEC countries
• Several products have been WHO prequaliﬁ ed or ERP 
approved (oxytocin, misoprostol)
Regulatory eﬃ  ciency
• All commodities have been included on the WHO Essential 
Medicines List
• A fast-track registration process was established for 
prequaliﬁ ed products in 23 countries
Supply and awareness
• Best-practice tools for harmonising and strengthening 
supply-chain management have been ﬁ nalised, including 
for private sector partnerships; country-level dissemination 
is underway
• A quantiﬁ cation and forecasting guide for all life saving 
commodities is available
• An integrated LMIS and HMIS platform has been developed 
and tested in Tanzania 
• Amoxicillin dispersible tablets for pneumonia have been 
registered in nine new countries and 30 countries have 
started procurement, which has increased by 500% since 
2012 
• 7·1% chlorhexidine digluconate for umbilical cord care has 
been registered in three new countries and is underway in 
several other countries
Demand and utilisation 
• Advocacy and demand-generation tool-kits have been 
developed to improve levels of information, awareness, and 
use of commodities
• Tool-kits are being widely disseminated, including in-
country dissemination in Uganda, Zambia, Nepal, 
Bangladesh, Democratic Republic of Congo, and 
Madagascar, to strengthen new or existing national 
strategies or programmes
Reaching women and children
• A mapping of ﬁ nancial access barriers and point-of-service 
exemption strategies has been initiated
Performance and accountability
• A compendium of high quality, adaptable, up-to-date 
training materials, job aids, and checklists have been 
developed for all 13 life saving commodities
(Panel continues on next page)
(Panel 1 continued from previous page)
Tanzania
• Expanded integrated LMIS to cover all regions 
• Registered amoxicillin dispersible tablets and misoprostol
• Updated standard treatment guidelines and Essential 
Medicines List
• Updated user-friendly family planning guidelines and an 
Integrated Management of Childhood Illness 
• Held provider consultations to increase use of antenatal 
corticosteroids
RMNCH=reproductive, maternal, newborn, and child health. UNCoLSC=UN Commission 
on Life Saving Commodities. eLMIS=electronic logistics management information system. 
LMIS=logistics management information system.
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coordination, which typically related to poor commodity 
security strategies. Eight of 12 had insuﬃ  cient regulatory 
capacity, usually because of poor pharmacovigilance or 
post-market surveillance systems. 
We commonly observed commodity-speciﬁ c bottle-
necks for regulatory eﬃ  ciency, health worker per-
formance and accountability, and supply and awareness. 
Regulatory bottlenecks were most common in 
reproductive and neonatal health commodities, and 
antenatal steroids and emergency contraceptives had 
regulatory bottlenecks in most countries. All countries 
had health worker performance gaps: despite having up-
to-date national curriculum and tools available, only half 
of facilities had recently trained staﬀ  (58%) or tools (53%) 
to support eﬀ ective service delivery, including job-aids 
and checklists (appendix).
Supply chain bottlenecks existed in all countries. 
Although most countries used appropriate forecasting 
tools, just one of 12 countries assessed had comprehensive 
logistics management systems to track commodities 
from central warehouses to service delivery points. 
National stock-outs were common for female condoms, 
misoprostol, and dispersible amoxicillin (table 2). 
Although data-gaps exist, an average of 40% of health 
facilities had stock-outs, with child health commodities 
most available and misoprostol, antenatal steroids, 
female condoms, and newborn resuscitation equipment 
out of stock in at least half of facilities. Finally, half of 
countries still report formal or informal user fees that 
constrain access to some or all of the 13 commodities. 
Data was not available for all countries for some 
indicators. Challenges in presenting the data are outlined 
in the discussion. 
Countries performed better in relation to demand 
generation, where eight of 12 countries had programmes 
in place. Nearly all (nine of 11) countries needed all public 
sector procurements to take place from a good-
manufacturing practice certiﬁ ed manufacturer.
In terms of the RMNCH country engagement process, 
and to advance the UNCoLSC mandate, the RMNCH Fund 
committed $175·7 million for 19 countries between Oct 7, 
2013, and Aug 15, 2015. This commitment included an 
initial wave of eight countries that received support in 2013 
and a second group of eleven countries that received 
support in a phased manner during 2014–15, with the 
duration of funding extending over a 1–3 year period. All 
countries in the plan were in sub-Saharan Africa except for 
Afghanistan, Bangladesh, and Pakistan. $24·9 million 
(39·0%) of resources were directed to cross-cutting system-
strengthening interventions such as improvement of supply 
chains, with the remaining balance fairly evenly split 
between maternal and neonatal joint care ($13·6 million, 
8%), family planning ($24·9 millioin, 14%), maternal health 
($17·6 million, 10%), neonatal health ($19·5 million, 11%), 
and child health categories ($31·9 million, 18%). 
$86·6 m (50·4%) of funds were committed to improve 
health worker performance and accountability, 
$53·3 million (30·3%) to strengthen supply chains, and 
$21·2 million (12·0%) to stimulate demand (ﬁ gure 4). 
3·4% of funds were directed to support regulatory eﬃ  ciency 
and quality improvements. Panel 1 provides a summary of 
achieve ments for an initial wave of eight countries where 
eﬀ orts have been in progress for at least 18 months. 
Global progress against UNCoLSC recommendations 
was supported through the work of the technical resource 
teams. All commodities are now formally listed on the 
WHO EML (panel 2). Global market-shaping eﬀ orts 
yielded substantial price reductions for implantable 
contraceptives, and the securing of additional manu-
facturers created potential competitive price reductions 
for neonatal resuscitation equipment. Manufacturers 
were identiﬁ ed for all commodities, including newly 
(Panel 2 continued from previous page)
• New, global adaptable tools (including job aids, posters, 
brochures, and videos) were designed for health providers 
to promote zinc and ORS, as well as chlorhexidine
• Over $200 million in new funding has been mobilised to 
support scale-up of integrated community case 
management of childhood illnesses in eight countries, which 
includes co-ﬁ nancing from a range of donors leveraging 
funding from the Global Fund New Funding model 
• A quality framework has been developed for neonatal 
resuscitation to enhance the quality of training and 
education programmes
• A global inventory of e-health and m-health tools and 
applications has been completed
Product innovation
• An agreement has been ﬁ nalised between UNICEF and WHO 
to allow oxytocin to be included in the cold-chain
• New upright newborn resuscitators have been developed 
and are now available on the global market 
• New patient-friendly product presentations for amoxicillin 
dispersible tablets for pneumonia have been developed and 
are being tested in eight high-burden countries
• Three-pack misoprostol developed and commercially 
available
• Ready-to-use packs are being evaluated to enhance the use 
of magnesium sulfate for pre-eclampsia and eclampsia, 
consisting of a loading dose pack and a maintenance pack
• Preliminary work on heat-stable inhaled oxytocin has been 
initiated
RMNCH=reproductive, maternal, newborn, and child health. UNCoLSC=UN Commission 
on Life Saving Commodities. eLMIS=electronic logistics management information system. 
HMIS=health management information system. GMP=good manufacturing practice. 
ERP=Expert Review Panel. ORS=oral rehydration solution. e-health=electronic health. 
m-health=mobile health.
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listed commodities such as dispersible amoxicillin and 
chlorhexidine, with manufacturers in south Asia and 
Africa supported to produce key RMNCH products. 
Global forecasts were done to estimate manufacturing 
and procurement needs and a fast-track registration 
process was established for WHO prequaliﬁ ed com-
modities. A post-market commodity survey across ten 
countries suggested that most UNCoLSC commodities, 
with the exception of oxytocin, were of reasonable quality. 
Agreements were secured between the Global Alliance 
for Vaccines and Immunization and UNICEF that allow 
oxytocin to be included in the vaccine cold-chains.9 Best-
practice materials were generated for a range of priorities 
including advocacy, demand generation, supply chain 
management, digital health, and health worker support 
(ie, training materials, job aids and checklists). Finally, 
innovations in product packaging and formulation 
supported the scale-up of amoxicillin dispersible tablets 
and misoprostol. 
Discussion
The 2015 Millennium Development Goal deadline 
represented a crucial opportunity to assess progress 
against key targets and identify remaining gaps. For the 
Global Strategy for Women’s and Children’s Health, the 
world fell short of achieving goals 4 and 5, saving just 
2·4 million of the projected 6 million lives of women and 
children in the past 5 years.10 As a contributing initiative 
to this strategy, the UNCoLSC has played a part at the 
nexus between global systems, countries, and markets to 
advance more eﬀ ective pricing, procurement, distri-
bution, and delivery of essential commodities. Although 
major advances have been achieved in implementing its 
recommendations, a substantial body of work remains.
Persistent commodity bottlenecks were common at the 
country level, including out-of-date EMLs, unregistered 
commodities, and restrictive guidelines and prescription 
authority, which limit distribution of commodities where 
they are needed most. Commodity security strategies 
were often poorly developed, and capacity to monitor the 
quality and safety of medicines is scarce. Although most 
national protocols and training materials were updated, 
dissemination to peripheral health facilities will need 
further eﬀ orts. The monitoring and distribution of com-
modities from national warehouses to service delivery 
points remains a barrier, with 40% of the 13 priority 
commodities out of stock at the time of assessment. 
Fragmented supply chains contribute to these challenges. 
For example in Kenya, 12 diﬀ erent types of health com-
modities are provided by at least 18 donor organisations, 
procured by 13 agencies, sent to ﬁ ve warehouses, and 
delivered through seven supply chains.11 
The UNCoLSC experience suggests that countries opted 
to ﬁ nance a balanced set of RMNCH priorities—from 
focused eﬀ orts to scale up implantable con traceptives to 
cross-cutting eﬀ orts to strengthen supply chains. 
Commodity procurement was de-emphasised, potentially 
because the 13 UNCoLSC commodities were low-cost and 
could be sustainably procured through national systems. 
Although frequent regulatory and quality assurance 
bottlenecks were identiﬁ ed at the country-level, they were 
not often prioritised, which suggests additional guidance 
and technical support could be appropriate. 
Most of the global milestones outlined in the original 
UNCoLSC Report and Implementation Plan have been 
achieved or are nearing completion. Key areas of progress 
include listing all commodities on the WHO EML; 
securing price reductions for implantable contraceptives; 
establishing a fast-track system to accelerate product 
registration; and generating means and materials to 
support advocacy, demand generation, and health worker 
training. However, progress is slower in other areas. 
National regulatory systems remain complex and 
ineﬃ  cient, creating disincentives for manufacturers to 
register commodities with low proﬁ t margins. Eﬀ orts to 
streamline and harmonise systems between countries, 
such as the African Medicines Regulatory Harmonization 
Programme, are crucial.12 Commodity procurement is 
often hindered by being out of line with domestic budget 
cycles, leading to national stock-outs.13 The feasibility of a 
revolving fund to support commodity procurement is 
under exploration. Finally, mechanisms to support quality 
assurance for essential medicines will require additional 
technical support from the global and regional levels.14,15 
The process of documenting the country status in 
relation to UNCoLSC recommendations highlighted often 
overlooked implementation barriers, but several limitations 
and information gaps are evident. First, the sub-Saharan 
African countries assessed might not adequately represent 
challenges experienced elsewhere on the continent or in 
other regions. Second, although eﬀ orts were made to 
capture the most up-to-date information since 2012, recent 
gains might not be adequately proﬁ led. Third, existing data 
sources in several areas are inadequate. For example, 
coverage data exist for child health and family planning 
(with the exception of emergency contraception), but there 
are few standard information sources to document delivery 
of maternal and neonatal interventions and the quality of 
care provided. Global eﬀ orts are underway to address these 
gaps.16 Fourth, country bottleneck identiﬁ cation depended 
upon the generation of categorical variables from non-
standard and sometimes qualitative data collected by 
diﬀ erent enumerators. Despite the use of expertly deﬁ ned 
performance thresholds to generate these variables, this 
process might be subject to interpretation and bias. Finally, 
although this assessment provides a snapshot of 
commodities and related systems, periodic updating will be 
essential to track change over time. 
Lessons learned from implementation of the UNCoLSC 
agenda carry important implications for the updated 
Global Strategy for Women’s, Children’s and Adolescents’ 
Health. The ﬁ rst priority is securing ﬁ nancing needed to 
support country plans. Estimates suggest an additional 
$28–30 billion per year is needed to close the gap across 
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75 high-priority countries.7 Under the umbrella of the new 
Global Financing Facility, a more sustainable mix of grant 
and loan-based support is envisioned to be channelled to 
countries based on prioritised reproductive, maternal, 
neonatal, child, and adolescent health (RMNCAH) 
investment cases. The second priority is the need for 
commodity perspectives to inform the development and 
monitoring of investment cases, and national plans to 
achieve the targets outlined in the updated Global Strategy. 
The commodity lens has provided a useful and actionable 
focus for identifying and addressing key bottlenecks; use 
of standard metrics to track commodity ﬂ ow highlights 
crucial gaps. Eﬀ orts to simplify and standardise the 
monitoring of country plans and investment cases, 
drawing from the UNCoLSC experience and other 
initiatives such as Countdown 2015, are essential.17 
Finally, the unﬁ nished components of the UNCoLSC 
mandate have the potential to inform an agenda for the so-
called global public good, where coordinated eﬀ orts at the 
global and regional levels provide complementary support 
to country implementation. This agenda should include 
market-shaping eﬀ orts to secure price reductions beyond 
the 13 commodities; the establishment of ﬁ nancing 
mechanisms to underwrite timely domestic commodity 
procurement; eﬀ orts to improve regulatory eﬃ  ciency 
through establishing product standards, harmonisation of 
guidelines, and support for joint inspections; and 
mechanisms to foster procurement of quality products, 
enhance post-market surveillance, and strengthen 
pharmacovigilance. Addressing supply chain gaps will 
require global eﬀ orts to reduce fragmentation and country 
action to improve forecasting, logistics management, and 
distribution. Finally, robust and sustained technical 
support should be made available to strengthen RMNCAH 
investment cases, ease country access to the latest evidence 
and best-practice materials, and enhance south–south 
exchanges and regional learning to support the 
implementation of nationally deﬁ ned priorities.
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